美股异动｜诺和诺德涨超2.5%，新型减肥药Cagrilintide三期试验结果积极

Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 2.5%, reaching a new high of $58.67 since late July, driven by positive results from a late-stage clinical trial of the new weight-loss drug Cagrilintide [1] Group 1: Clinical Trial Results - Cagrilintide, administered as a once-weekly injection, helped patients achieve an average weight loss of 11.8% after 68 weeks, compared to only 2.3% in the placebo group [1] - The drug demonstrated good tolerability, with the most common side effects being gastrointestinal reactions, mostly mild to moderate in severity [1]